Literature DB >> 28890821

Feasibility and reproducibility of substituting oral contrast with water for duodenal volume delineation in patients undergoing pancreatic stereotactic body radiotherapy.

Guangyin Wu1,2, Vivek Verma1, Matthias F Haefner3, Sicong Li1, Chi Lin1.   

Abstract

BACKGROUND: This is the first known report evaluating the feasibility of substituting oral contrast with water in efforts to delineate the duodenum for pancreatic stereotactic body radiotherapy (SBRT).
METHODS: From January 2015 to August 2016, 13 patients were simulated after ingestion of 8 ounces of water approximately 15-20 min prior to their simulation scan. We examined the feasibility of contouring the duodenum thereafter, and measured the duodenal volume as well as its variation. Comparison was made to 40 patients treated from January 2009 to February 2012 on a prospective trial who used oral contrast. Group comparisons were performed by the Mann-Whitney U test.
RESULTS: The duodenum was identified in all 13 patients who used water instead of oral contrast without subjective difficulty. In this group, the median duodenal volume was 72.86 cm3 (range, 44.61-130.90 cm3). In the oral contrast group, median duodenal volume was 86.21 cm3 (range, 50.11-157.89 cm3) There were no significant differences between groups (P=0.115). The approach was reproducible, as all patients were able to drink the same amount of water 15-20 min prior to each SBRT fraction to keep duodenal volumes subjectively similar to volumes on the simulation CT scan.
CONCLUSIONS: This novel approach is effective and reproducible in delineating the duodenum for treatment planning and daily setup.

Entities:  

Keywords:  Stereotactic body radiotherapy (SBRT); duodenum; pancreatic cancer; stereotactic ablative radiotherapy; toxicity

Year:  2017        PMID: 28890821      PMCID: PMC5582030          DOI: 10.21037/jgo.2017.04.03

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  17 in total

1.  Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trial.

Authors:  Vivek Verma; Audrey J Lazenby; Dandan Zheng; Abhijeet R Bhirud; Quan P Ly; Chandrakanth Are; Aaron R Sasson; Chi Lin
Journal:  Radiother Oncol       Date:  2017-01-12       Impact factor: 6.280

2.  Dosimetric benefit of adaptive re-planning in pancreatic cancer stereotactic body radiotherapy.

Authors:  Yongbao Li; Jeremy D P Hoisak; Nan Li; Carrie Jiang; Zhen Tian; Quentin Gautier; Masoud Zarepisheh; Zhaoxia Wu; Yaqiang Liu; Xun Jia; Jona Hattangadi-Gluth; Loren K Mell; Steve Jiang; James D Murphy
Journal:  Med Dosim       Date:  2015-05-19       Impact factor: 1.482

3.  Radiotherapy technical considerations in the management of locally advanced pancreatic cancer: American-French consensus recommendations.

Authors:  Florence Huguet; Karyn A Goodman; David Azria; Severine Racadot; Ross A Abrams
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-08-01       Impact factor: 7.038

4.  Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer.

Authors:  Devin Schellenberg; Jeff Kim; Claudia Christman-Skieller; Carlene L Chun; Laurie Ann Columbo; James M Ford; George A Fisher; Pamela L Kunz; Jacques Van Dam; Andrew Quon; Terry S Desser; Jeffrey Norton; Annie Hsu; Peter G Maxim; Lei Xing; Karyn A Goodman; Daniel T Chang; Albert C Koong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-05-05       Impact factor: 7.038

5.  Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas.

Authors:  Daniel T Chang; Devin Schellenberg; John Shen; Jeff Kim; Karyn A Goodman; George A Fisher; James M Ford; Terry Desser; Andrew Quon; Albert C Koong
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

6.  Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.

Authors:  Michael D Chuong; Gregory M Springett; Jessica M Freilich; Catherine K Park; Jill M Weber; Eric A Mellon; Pamela J Hodul; Mokenge P Malafa; Kenneth L Meredith; Sarah E Hoffe; Ravi Shridhar
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-04-05       Impact factor: 7.038

7.  Stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreas.

Authors:  Chris E Lominska; Keith Unger; Nadim M Nasr; Nadim Haddad; Greg Gagnon
Journal:  Radiat Oncol       Date:  2012-05-18       Impact factor: 3.481

8.  Having Your Cake and Eating It Too: Combining SBRT and Multi-agent Chemotherapy in Locally Advanced Pancreatic Cancer.

Authors:  Amar Kishan; Percy Lee
Journal:  Cureus       Date:  2016-07-13

Review 9.  Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy.

Authors:  Jimm Grimm; Tamara LaCouture; Raymond Croce; Inhwan Yeo; Yunping Zhu; Jinyu Xue
Journal:  J Appl Clin Med Phys       Date:  2011-02-08       Impact factor: 2.243

10.  Stereotactic body radiotherapy in the treatment of pancreatic adenocarcinoma in elderly patients.

Authors:  Carolyn H Kim; Diane C Ling; Rodney E Wegner; John C Flickinger; Dwight E Heron; Herbert Zeh; Arthur J Moser; Steven A Burton
Journal:  Radiat Oncol       Date:  2013-10-16       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.